Semaglutide is a prescription medication that mimics a natural gut hormone called GLP-1 to help control blood sugar and reduce appetite. Originally developed for type 2 diabetes, it has become one of the most widely prescribed drugs for weight management. It’s sold under three brand names, all made by Novo Nordisk: Ozempic and Rybelsus for diabetes, and Wegovy for weight loss and cardiovascular risk reduction.
How Semaglutide Works in Your Body
After you eat, your gut naturally releases a hormone called GLP-1 that signals your pancreas to produce insulin and tells your brain you’re getting full. Semaglutide is a synthetic version of this hormone, engineered to last much longer in your bloodstream. Where natural GLP-1 breaks down within minutes, semaglutide stays active for about a week.
It works on three fronts simultaneously. In the pancreas, it triggers insulin release only when blood sugar is elevated, which means it carries a low risk of causing dangerously low blood sugar on its own. It also dials back glucagon, a hormone that raises blood sugar, and promotes the growth of insulin-producing cells. In the digestive system, it slows the rate at which your stomach empties food into the intestines, which keeps you feeling full longer after meals. In the brain, it acts on the hypothalamus to reduce hunger signals, curb food cravings, and amplify feelings of satisfaction from eating.
The Three Brand Names and What They Treat
Though they all contain semaglutide, the three brand names are approved for different conditions and are not interchangeable.
Ozempic is a once-weekly injection approved for adults with type 2 diabetes. Beyond blood sugar control, it’s also approved to reduce the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and established heart disease. A more recent approval added kidney protection for people with type 2 diabetes and chronic kidney disease.
Rybelsus is the oral tablet form, taken daily rather than weekly. It carries the same core approvals as Ozempic for blood sugar management and cardiovascular risk reduction in type 2 diabetes, but it comes with specific instructions that matter for absorption. You need to take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medications. Skipping this step significantly reduces how much of the drug your body absorbs.
Wegovy is specifically approved for weight management in adults with obesity (BMI of 30 or higher) or those who are overweight (BMI of 27 or higher) with at least one weight-related health condition. It’s also approved for adolescents aged 12 and older with obesity. Wegovy carries additional approvals for reducing cardiovascular events in adults with heart disease who are overweight or obese, and for treating a form of fatty liver disease called MASH (previously known as NASH) with moderate to advanced scarring.
What the Clinical Data Shows
For blood sugar control, semaglutide has been tested across multiple large trials. In the SUSTAIN trial series, the injectable form reduced HbA1c, a marker of average blood sugar over three months, by 0.38 to 1.07 percentage points more than comparator treatments. That’s a clinically meaningful drop, enough to move many patients from poorly controlled diabetes into a healthier range.
For weight loss, the drug is given at a higher dose (2.4 mg weekly for Wegovy, compared to a maximum of 2 mg for Ozempic). People in clinical trials typically lost 15% or more of their body weight over about 16 months. Importantly, this weight loss was achieved alongside a reduced-calorie diet and increased physical activity, not from the drug alone. Weight tends to return if the medication is stopped, which is why it’s generally considered a long-term treatment.
How the Dose Ramps Up
Semaglutide for weight loss starts at a low dose and increases gradually over about 16 to 20 weeks. The starting dose is 0.25 mg once weekly, primarily to let your body adjust and minimize side effects. Every four weeks, the dose steps up: 0.5 mg, then 1 mg, then 1.7 mg, and finally the maintenance dose of 2.4 mg.
If side effects are difficult at any step, your prescriber can pause the escalation for an additional four weeks before trying again. If the full 2.4 mg dose remains intolerable, a temporary drop to 1.7 mg with a later retry is an option. If the maintenance dose still can’t be tolerated, the medication is typically discontinued rather than kept at a lower dose indefinitely.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects, which makes sense given that the drug works partly by slowing digestion. Across clinical trials of GLP-1 drugs in this class, nausea is the most common complaint, affecting roughly 1 in 5 participants. Diarrhea occurs in about 11%, vomiting in 9%, indigestion in about 9%, and constipation in about 8%. Reduced appetite, reported in about 5% of participants, is often considered both a side effect and part of the intended therapeutic effect.
These symptoms are generally worst during the dose-escalation phase and tend to improve as the body adjusts. Eating smaller meals, avoiding high-fat or greasy foods, and staying hydrated can help. Most people find the side effects manageable enough to continue treatment, but a small percentage do discontinue because of persistent nausea or vomiting.
Important Safety Concerns
Semaglutide carries a boxed warning, the most serious type of FDA safety alert, regarding thyroid tumors. In animal studies, the drug caused thyroid C-cell tumors at doses comparable to what humans take. Whether this translates to a real risk in people remains unknown, but the warning led to a firm rule: semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, or a rare hereditary condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, shortness of breath, or persistent hoarseness while taking semaglutide, those symptoms warrant prompt medical attention.
Other notable risks include pancreatitis (inflammation of the pancreas), gallbladder problems, and, in people with diabetes who also take insulin or certain other diabetes medications, an increased risk of low blood sugar. There have also been reports of kidney injury, sometimes triggered by severe dehydration from persistent vomiting or diarrhea. Semaglutide should not be used during pregnancy, as animal studies have shown harm to developing offspring.
Injectable vs. Oral: Practical Differences
The weekly injection (Ozempic or Wegovy) uses a prefilled pen that you administer yourself in the thigh, abdomen, or upper arm. You can take it any day of the week, at any time of day, with or without food. Many people find the once-weekly schedule easier to stick with than a daily pill.
The oral version (Rybelsus) avoids needles but demands more from your daily routine. The empty-stomach requirement and 30-minute waiting period aren’t optional. Taking it with food, with coffee, or with other medications noticeably reduces how much drug gets into your bloodstream. For people who travel frequently, have unpredictable morning schedules, or take several morning medications, this can be a real practical hurdle.